Posters

      Data sharing and meta-analysis of in vitro toxicology assessment of diverse e-liquid and heat-not-burn platforms on the INTERVALS platform

      Boue, S.; Stan, A.; Hoeng, J.; Peitsch, M. C.

      Conference date
      Sep 9, 2019
      Conference name
      EUROTOX 2019
      Link to more information
      Topic
      Summary

      Extensive scientific studies are conducted to assess the relative risks of various candidate modified risk tobacco products compared with those of smoking cigarettes. As the scientific community conducts such assessments for diverse products and in a variety of laboratory models, knowledge on toxicity is spread across numerous scientific articles. We believe that by fostering the consolidation of data and knowledge gained from studies assessing novel tobacco/nicotine delivery products on a community platform, new hypotheses may be generated, and the weight of evidence may be increased. Therefore, we have created and are further developing INTERVALS (www.intervals.science), an online platform supporting independent, third-party collaboration by proactively sharing detailed protocols, tools, and data from assessment studies. Data files are accompanied by relevant information to foster reproducible research and encourage data reanalysis. We will present a meta-analysis of in vitro toxicology assessment studies, including aerosol characterization, neutral red uptake assay, and mouse lymphoma assay, for various e-liquid and heat-notburn platforms compared with the 3R4F reference cigarette. These studies have been conducted by multiple organizations using different methods and models. The content of the separate publications has been curated and included in INTERVALS in an interoperable format so that a metaanalysis of results can be performed. The direct comparison of the platforms tested in separate studies with different study designs (e.g., different lists of chemicals quantified in the aerosols) makes it difficult to compare every single result across all individual studies. However, the overall result is consistent in that all of the studies included in this analysis demonstrate the reduction of harmful or potentially harmful chemicals and of toxicity assessed in vitro for the tested platforms compared with cigarettes. As the scientific community integrates more studies and datasets into INTERVALS, it will become easier to conduct such meta-analyses and review results obtained across institutions, models, and platforms.

      Related Publications

      Tobacco Heating System 2.4 has less harmful impact on 2D bone co-culture system than cigarette smoke

      Pre-clinical Toxicology

      Characterizing the Genotoxic Potential of E-Cigarette Components In Vitro

      Pre-clinical Toxicology

      Evaluation of Chronic Toxicity and Carcinogenicity of Flavored E-Vapor Aerosols in an 18-Month Inhalation Study in A/J Mice

      Pre-clinical Toxicology

      Toxicological Assessment of Highly Mentholated Reduced-Risk Tobacco Products in Sprague Dawley Rats Following Sub-Chronic Inhalation Exposure

      Pre-clinical Toxicology

      Exposure to a Heated Tobacco Product Aerosol Is Associated with Lower Activity of Hepatic Cytochrome P450 Enzymes and Reduced Alteration in Clozapine Metabolism Than Exposure to Cigarette Smoke

      Pre-clinical Toxicology

      Evaluation of Chronic Inhalation Toxicity of E-Vapor Aerosols in an 18-Month Study in AJ Mice

      Pre-clinical Toxicology

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.